Broad Market Gains Hold Steady
Markets extended their momentum from Tuesday's rally, with the major indices closing the session in positive territory despite pulling back from the day's highs. The Nasdaq led the way, closing up more than 1%, while the Dow Jones Industrial Average added roughly half a percent. The session reflected a market still searching for direction but leaning cautiously optimistic heading into the final trading day of the week, with jobless claims data on the horizon.
Nike Hits an 11-Year Low Despite Earnings Beat
Perhaps the most striking move of the day came from Nike, whose shares plummeted over 15% to reach a historic 11-year low — making it the worst performer on the S&P 500 for the session. What makes this decline particularly notable is that Nike actually posted an earnings beat. Under normal circumstances, exceeding expectations would buoy a stock, but investors expressed deep frustration with the pace and effectiveness of the company's turnaround strategy.
Adding to the pressure, concerns mounted that Nike's presence in China is falling behind competitors. For a brand that has long relied on international growth to drive revenue, losing ground in one of the world's largest consumer markets is a significant red flag. The selloff signals that Wall Street wants more than modest earnings surprises — it wants a credible roadmap for sustained recovery.
Eli Lilly Advances in the GLP-1 Weight Loss Race
On the opposite end of the spectrum, Eli Lilly shares surged more than 3.5% after the FDA approved its new oral weight loss pill, which is set to begin shipping on April 6th. This approval adds another product to the healthcare giant's growing GLP-1 roster and reinforces its position as a dominant player in one of the most lucrative pharmaceutical markets in recent memory.
The GLP-1 space has become fiercely competitive, with multiple companies vying for market share in weight loss and diabetes treatments. An oral formulation is particularly significant because it offers patients a more convenient alternative to injectable treatments, potentially broadening the addressable market. Eli Lilly's ability to continue expanding its product line in this category gives it a meaningful competitive edge going forward.
Microsoft and Chevron Plan a $7 Billion Energy Center
In a deal that underscores the growing intersection of technology and energy, Microsoft entered exclusive talks with Chevron to construct a massive energy center in West Texas. According to reporting from Bloomberg, the facility would provide power for a large data center campus, with an initial capacity of 2,500 megawatts of electricity and an estimated cost of roughly $7 billion.
This partnership highlights a critical challenge facing the tech industry: the insatiable energy demands of artificial intelligence and cloud computing. As companies like Microsoft continue to scale their AI infrastructure, securing reliable and abundant power sources has become a strategic priority. Partnering with an energy major like Chevron represents a pragmatic approach to solving this bottleneck, though it also raises questions about the energy mix and sustainability commitments that will define these massive facilities.
Looking Ahead
With jobless claims data due on the final trading day of the week, investors will be watching closely for signals about the health of the labor market. For now, the market's ability to sustain its rally amid sharply divergent individual stock moves suggests a market driven more by sector-specific narratives than broad macro sentiment — a dynamic likely to persist as earnings season progresses and economic data continues to roll in.